四抗原金黄色葡萄球菌疫苗(SA4Ag)的安全性、耐受性与免疫原性:首次人体随机安慰剂对照1/2期研究结果
本研究为双盲、申办者非盲、安慰剂对照1/2期研究,454名18-64岁健康成人随机接受单剂SA4Ag(三种配方,rP305A剂量递增)或安慰剂。SA4Ag受试者第29天多数达到各抗原预设抗体阈值,rP305A呈剂量依赖性免疫应答,cLIA滴度最高升高18倍,OPA滴度对5型和8型荚膜多糖菌株分别升高>80倍和>20倍,抗体应答持续至第12个月,SA4Ag耐受良好,未报告疫苗相关严重不良事件。
要点
- SA4Ag单剂接种在18-64岁健康成人中安全诱导快速、强效功能性免疫应答。
- rP305A免疫应答呈剂量依赖性,第29天cLIA滴度最高升高18倍。
- OPA滴度对5型和8型荚膜多糖菌株分别升高>80倍和>20倍,抗体持续至第12个月。
核心结论
- SA4Ag单剂接种在18-64岁健康成人中安全诱导快速、强效功能性免疫应答,且应答持续至第12个月,支持该疫苗进一步开发。
研究设计与样本
- 双盲、申办者非盲、安慰剂对照1/2期研究,454名18-64岁健康成人随机接受单剂SA4Ag三种配方之一(rP305A剂量递增)或安慰剂。
主要发现
- SA4Ag受试者中高比例在第29天达到各抗原预设抗体阈值。
- rP305A观察到显著且剂量依赖的免疫应答,第29天cLIA滴度最高升高18倍。
- 第29天OPA试验滴度对表达荚膜多糖5型的金黄色葡萄球菌菌株升高>80倍,对表达8型的菌株升高>20倍。
- 抗体应答持续至第12个月,从第11-15天达到的峰值逐渐减弱。
- SA4Ag耐受良好,未报告疫苗相关严重不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A prophylactic Staphylococcus aureus four-antigen vaccine (SA4Ag) is under development for prevention of invasive S. aureus disease. A preliminary S. aureus three-antigen vaccine (SA3Ag) was reformulated to include a novel manganese transporter protein (MntC or rP305A). This study describes the first-in-human dose-finding, safety, and immunogenicity results for SA4Ag. METHODS: In this double-blind, sponsor-unblind, placebo-controlled, phase 1/2 study, 454 healthy adults aged 18-64years were randomised to receive a single dose of one of three formulations of SA4Ag with escalating dose levels of rP305A or placebo. Functional immune responses were measured using opsonophagocytic activity (OPA) killing and fibrinogen-binding inhibition (FBI) assays; antigen-specific immunogenicity was assessed using a four-plex competitive Luminex® immunoassay (cLIA). RESULTS: A high proportion of SA4Ag recipients met the pre-defined antibody thresholds for each antigen at Day 29. A substantial and dose-level dependent immune response was observed for rP305A, with up to 18-fold rises in cLIA titres at Day 29. Robust functional responses were demonstrated, with >80-fold and >20-fold rises in OPA assay titres at Day 29 using S. aureus strains expressing capsular polysaccharide serotypes 5 and 8, respectively. Durable antibody responses were observed through month 12, gradually waning from peak levels achieved by days 11-15. SA4Ag was well tolerated, and no vaccine-related serious adverse events were reported. CONCLUSIONS: Single-dose vaccination of SA4Ag in healthy adults aged 18-64years safely induced rapid and robust functional immune responses that were durable through month 12, supporting further development of this vaccine. TRIAL REGISTRATION NUMBER: NCT01364571.
引用
- Frenck RW, Creech CB, Sheldon EA, et al. Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study. Vaccine. 2016. PMID: 27916408. doi:10.1016/j.vaccine.2016.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。